<DOC>
	<DOC>NCT01347944</DOC>
	<brief_summary>The purpose of this study is to collect clinical and laboratory data for patients affected by intermediate 1 and low risk Myelodysplastic Syndrome (MDS) associated by deletion 5q who were prescribed Revlimid from 31October 2008 to present. Revlimid is available in Italy for these patients since October 2008 based on a local disposition of the Italian Drug Agency (AIFA) issued according to a National law named 648/96.</brief_summary>
	<brief_title>MORE - Monitoring Revlimid - Collecting of Patient Information From Myelodysplastic Syndrome (MDS) Italian National Registry</brief_title>
	<detailed_description>There will be retrospective collection and integration of clinical laboratory data as well as prospective data collection on the same patients.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>intermediate 1 and low risk MDS patients associated with: 1. transfusion dependency anemia (at least 2 units per 8 weeks before starting of Revlimid treatment ) 2. 5q3133 deletion isolated or associated to other chromosomal abnormalities. patients with serum creatinine &gt; 2.5mg/dl child bearing potential females who do not use adequate contraceptive methods</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>MORE</keyword>
	<keyword>Monitoring Revlimid</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>Transfusion-dependent anemia</keyword>
	<keyword>5q deletion</keyword>
	<keyword>lenalidomide</keyword>
</DOC>